This document discusses the neurobiology of schizophrenia. It covers the dopamine, serotonin, glutamate, and other neurotransmitter pathways involved in the disorder. The dopamine hypothesis proposes that dopamine is dysregulated in schizophrenia, being either overactive, underactive, or "out of tune" in different brain areas. This leads to both positive and negative symptoms. The document outlines key brain regions and circuits impacted, including the prefrontal cortex, mesolimbic pathway, and others. It also discusses various pharmacological targets for antipsychotic drugs that aim to modulate these neurotransmitter systems.